Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19815204 | 0.92 | TYMP (0.30) | TYMP | |
| SCHEMBL19825396 | 0.92 | TYMP (0.30) | TYMP | |
| SCHEMBL19817402 | 0.92 | TYMP (0.30) | TYMP | |
| SCHEMBL23425409 | 0.91 | TYMP (0.35) | TYMP | |
| SCHEMBL23827226 | 0.90 | TYMP (0.34) | TYMP | |
| SCHEMBL23827224 | 0.90 | TYMP (0.34) | TYMP | |
| SCHEMBL5993262 | 0.88 | TYMP (0.34) | TYMP | |
| SCHEMBL31196681 | 0.87 | KDM4E (0.36) | TYMP | |
| SCHEMBL5570589 | 0.87 | — | — | |
| SCHEMBL23827205 | 0.86 | TYMP (0.32) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492390-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2013-07-23 | — | — | US | disclosed |
| US-20120165514-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S (DK) | 2012-06-28 | — | — | US | disclosed |
| US-8084458-B2 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2011-12-27 | — | — | US | disclosed |
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA A/S, a Denmark corporation | 2010-08-26 | — | — | US | disclosed |
| US-7569575-B2 | Formed via intermediates which are reactive with nucleophiles | SANTARIS PHARMA A/S (DK) | 2009-08-04 | — | — | US | disclosed |
| EP-1501848-B1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | SANTARIS PHARMA AS (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | SANTARIS PHARMA A/S (DK) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216983-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | RNGTT, NSUN3, NSUN2 | TYMP 67/4885 |
| US-20120165514-A1 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES | RNGTT, NSUN3, NSUN2 | TYMP 67/4885 |
| US-20040014959-A1 | Synthesis of locked nucleic acid derivatives | NSUN3, RNGTT, NSUN2 | TYMP 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.